Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jan;38(1):92-102.
doi: 10.1016/j.lpm.2008.09.016. Epub 2008 Nov 11.

[Acromegaly]

[Article in French]
Affiliations
Review

[Acromegaly]

[Article in French]
Philippe Chanson. Presse Med. 2009 Jan.

Abstract

Acromegaly is a rare disease usually caused by growth hormone (GH) hypersecretion, due to a pituitary adenoma; in very rare cases, acromegaly is due to ectopic secretion of GHRH, responsible for pituitary hyperplasia. Owing to its insidious onset, acromegaly is often diagnosed late (4 to > 10 years after onset), at an average age of about 40 years, in front of an acquired, slowly progressing disfigurement mainly involving the face and extremities. Acromegaly has also rheumatologic, cardiovascular, respiratory and metabolic consequences which determine its prognosis. The diagnosis is based on an increased serum GH concentration unsuppressed following an oral glucose load (oral glucose tolerance test -OGTT-) and an increased insulin-like growth factor-I (IGF-I); according to a 2000 Consensus statement, if the basal serum GH is above 0,4microg/L (1.2mIU/L) and/or if the IGF-I is elevated, an OGTT must be performed. If the lowest GH value (nadir) during OGTT remains above 1microg/L (3mIU/L), acromegaly is confirmed. With the generalized use of very sensitive assays nowadays, it has recently been considered that this cutoff should be decreased to 0,3microg/L (0.9mIU/L). Treatment is aimed at correcting (or preventing) tumor compression by excising the culprit lesion, and at reducing GH and IGF-I levels to normal values (or at least to a "safe" GH level of < 2microg/L or < 6mIU/L). A stepwise therapeutic strategy is used: transsphenoidal surgery is often the first-line treatment; when surgery fails to correct GH/IGF-I hypersecretion, medical treatment with somatostatin analogs and/or radiotherapy can be used, somatostatin analogs being generally preferred; the GH antagonist (pegvisomant) is used in patients that are resistant or intolerant to somatostatin analogs. Prognosis of acromegaly has improved in the recent years: adequate hormonal disease control is achieved in most cases, allowing life expectancy similar to that of the general population.

PubMed Disclaimer

Similar articles

  • Acromegaly.
    Chanson P, Salenave S. Chanson P, et al. Orphanet J Rare Dis. 2008 Jun 25;3:17. doi: 10.1186/1750-1172-3-17. Orphanet J Rare Dis. 2008. PMID: 18578866 Free PMC article. Review.
  • Acromegaly.
    Chanson P, Salenave S, Kamenicky P. Chanson P, et al. Handb Clin Neurol. 2014;124:197-219. doi: 10.1016/B978-0-444-59602-4.00014-9. Handb Clin Neurol. 2014. PMID: 25248589 Review.
  • Pituitary tumours: acromegaly.
    Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J. Chanson P, et al. Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5):555-74. doi: 10.1016/j.beem.2009.05.010. Best Pract Res Clin Endocrinol Metab. 2009. PMID: 19945023 Review.
  • Acromegaly.
    Scacchi M, Cavagnini F. Scacchi M, et al. Pituitary. 2006;9(4):297-303. doi: 10.1007/s11102-006-0409-4. Pituitary. 2006. PMID: 17077948 Review.
  • Hormonal diagnosis of GH hypersecretory states.
    Grottoli S, Gasco V, Ragazzoni F, Ghigo E. Grottoli S, et al. J Endocrinol Invest. 2003;26(10 Suppl):27-35. J Endocrinol Invest. 2003. PMID: 15497657 Review.

Cited by

Substances

LinkOut - more resources